Relevance of SARS-CoV-2 induced cross-reactive antibodies for HIV diagnostics

Relevance of SARS-CoV-2 induced cross-reactive antibodies for HIV diagnostics - ITHF-2-diagnostic

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028754

Enrollment

Registered

2022-04-08

Start date

2022-03-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Confirmed past or current SARS-CoV-2 infection, no vaccination against SARS-CoV-2: Collection of plasma and serum samples Group 2: Confirmed past or current SARS-CoV-2 infection, vaccination

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnostically confirmed SARS-CoV-2 infection previous to or at the time of sampling.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Reactivity of samples in diverse screening and confirmatory HIV diagnostic tests	—

Countries

Germany

Contacts

Public ContactMargarethe Konik

Universitätsklinikum Essen, Klinik für Infektiologie

margarethe.konik@uk-essen.de+49 201/723-3394

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026